TREATMENT CELLS

Brand Owner (click to sort) Address Description
PER.C6 JANSSEN VACCINES & PREVENTION B.V. ARCHIMEDESWEG 4 2333 CN LEIDEN Netherlands Treatment of cells, chemical solutions, DNA delivery vehicles, proteinaceous molecules and nucleic acids for use in the preparation of pharmaceuticals and/or genetic biochemicals;Apparatus, namely, cell and cell-line cultivators;In the statement, Column 1, line 15, after LIKE , [comma] should be deleted. In the statement, Column 2, lines 17 and 18, should be deleted, and, OWNER OF CTM REGISTRATION NO. 001008333, DATED 4-14-2000, EXPIRES 12-4-2008. should be inserted.;Cells, cell-lines, and culture media for the cultivation of cells, for medical or clinical use, like genetherapy;PER C6;Cells and cell-lines for scientific, laboratory or medical research and for the use in the manufacture of pharmaceuticals;Scientific services namely research in the medical and biochemical field, especially the examination and testing of genes, pharmaceutical and biochemical semi-finished products, test systems for cells and cell-lines; culture media for cultivation of cells and cell-lines; genetically modified material, for use in medicines genetherapy, gene banks and diagnostic purposes, and for the development of medicines, genetherapy, gene banks and diagnostic purposes;
PER.C6 CRUCELL HOLLAND B.V. Archimedesweg 4 2333CN Leiden Netherlands Treatment of cells, chemical solutions, DNA delivery vehicles, proteinaceaous molecules and nucleic acids for use in the preparation of pharmaceuticals and/or genetic biochemicals;Cells, cell-lines and culture media for the cultivation of cells, for medical or clinical use, pharmaceutical products, namely, viruses, viral vectors, therepeutic proteins and vaccines;PER.C SIX;Scientific services, namely, research in the medical and biochemical field, namely, the examination and testing of genes, pharmaceutical and biomedical semi-finished products, test systems for cells and cell-lines; culture media for cultivation of cells and cell-lines; genetically modified materials for the development of medicines, gene banks and diagnostic purposes, services for third parties for preparation and production of unfinished pharmaceutical products, cell line generation and cell banking;
PER.C6 CRUCELL HOLLAND B.V. Archimedesweg 4 2333CN Leiden Netherlands Treatment of cells, chemical solutions, DNA delivery vehicles, proteinaceaous molecules and nucleic acids for use in the preparation of pharmaceuticals and/or genetic biochemicals;Cells, cell-lines and culture media for the cultivation of cells, for medical or clinical use, pharmaceutical products, namely, viruses, viral vectors, therapeutic proteins and vaccines;PER.C SIX;The applicant claims color as a feature of the mark, namely, ---, ---, ---.;Scientific services, namely, research in the medical and biochemical field, namely, the examination and testing of genes, phamaceutical and biomedical semi-finished products, test systems for cells and cell-lines; culture media for cultivation of cells and cell-lines; genetically modified materials for the development of medicines, gene banks and diagnostic purposes, services for third parties for preparation and production of unfinished pharmaceutical products, cell line generation and cell banking;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and/or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment.